摘要
目的 :探讨CYFRA2 1 1在肺癌、喉癌和消化道肿瘤中的诊断价值。方法 :应用酶联免疫方法对82例肺癌、18例喉癌和 74例消化道肿瘤测试血清CYFRA2 1 1水平。结果 :①肺癌CYFRA2 1 1阳性率为 79.3% ,特异性为 92 .5% ,准确率为 83.6 % ,明显高于其他肿瘤 ;②肿瘤转移患者血清CYFRA2 1 1水平明显高于未转移患者 ;③肺癌治疗前后血清CYFRA2 1 1水平有显著差异 ,治疗后明显下降 ;④非小细胞肺癌血清CYFRA2 1 1水平明显高于小细胞肺癌。结论 :CYFRA2 1 1是诊断肺癌 ,特别是非小细胞肺癌 ,以及观察疗效的一项极有价值的指标。
Objective:To explore the diagnostic value of CYFRA21 1 in pulmonary carcinoma,laryngeal carcinoma and digestive tract neoplasm Methods:We used ELISA method to detect serum CYFRA21 1 of 82 pulmonary carcinoma patients,18 laryngeal carcinoma patients and 74 digestive tract neoplasm patients Results:①The CYFRA21 1 positive rate,speciality and accuracy of pulmonary carcinoma are higher than those of other groups;②The CYFRA21 1 level of metastatic pulmonary carcinoma patients is higher than those of non metastatic groups( P <0.000 1);③The CYFRA21 1 levels of pulmonary carcinoma patients pretreated are higher than those of post treated patients( P <0.05);④The CYFRA21 1 levels of NSCLC patients are higher than those of SCLC patients Conclusions:CYFRA21 1 is a very valuable marker to diagnose pulmonary carcinoma (especially NSCLC)and to estimate the effect of treatment
出处
《肿瘤防治杂志》
2000年第2期116-117,共2页
China Journal of Cancer Prevention and Treatment
关键词
肿瘤
诊断
肿瘤标志物
CYFRA21-1
肺癌
喉癌
CYFRA21 1
pulmonary carcinoma
laryngeal carcinoma
digestive tract neoplasm
tumor marker.
